|
Global Vaccine Market and Cervical Cancer Vaccine Market Future Forecast
By Chandra B. Prasad
Renub Research
Email: c.prasad@renub.com
Tuesday - June 9, 2009
Globally cervical cancer is the third biggest female cancer killer disease after breast and lung cancer. Globally more than 250,000 women die annually from cervical cancer, 99 percent caused by human papillomavirus (HPV). Women in the age group of 15 to 45 are most affected and most of the deaths occur in the developing country. But the good news is that there is now a way to stop cervical cancer before it starts with vaccination against the human papillomavirus. Gardasil of Merck and Cervarix of GlaxoSmithKline are the two vaccines which are available in the market.
Both of these vaccines aim two types (16 and 18) of HPV causing nearly 70 percent of cervical cancers, with an efficacy of about 98 percent. But Gardasil has an edge over Cervarix it blocks two other types (6 and 11) of HPV responsible for approximately 90 percent of genital warts. Both of these vaccines Gardasil and Cervarix have WHO pre-qualification. WHO pre-qualification means that GARDASIL is now eligible for procurement by the United Nations Children's Fund (UNICEF) and other United Nations (UN) agencies including the Pan American Health Organization (PAHO), for use in national immunization programs.
Report Details
World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments published by Renub Research talks about the world vaccine market. This report gives the past, present scenario on the vaccines market and also forecast on future of vaccines market. Such as market size of Hepatitis B vaccines, Pneumococcal vaccines, Cervical Cancer vaccines etc. are there in the report. Forecast for the future market size of vaccine for diseases like Malaria, Ebola, Tuberculosis (TB), Japanese Encepha litis, West Nile, Typhoid etc. which are yet to be launched in the market have also been included in the report. The report also forecast on the sales of the key vaccines brands like Gardasil, Fluzone/Vaxigrip/Mutagrip, Prevnar, RotaTeq, Rotarix etc. Major companies' vaccines sales data for the year 2007 and 2008 are also there in the report.
Market Overview
The vaccines landscape is very different now as compared to few years back. With increasing public awareness about preventive healthcare and increased spending by governments for the same has once again put spotlight on the vaccines. Quality of life is expected to increase markedly with introduction of newer vaccines covering more and more diseases. Due to this vaccines, which were perceived as low margin business before, have now emerged as one of the most lucrative segments in the pharmaceutical industry. Moreover with the success of a number of blockbuster products, the market place has changed dramatically. Pharma major's today look upon vaccines as a driver for their future growth.
Already vaccines have become big business for pharmaceutical giants like GlaxoSmithKline, sanofi pasteur and Merck & Co.. For e.g. GSK Bio, GSK's vaccines arm, accounted for 8.4 percent of GSK's pharmaceutical turnover in 2006. And it is expected that by 2012 companies like GSK, Sanofi-aventis, Merck & Co., and Wyeth vaccines arm will fetch them more than 10 percent of sales from vaccine as a percentage of overall pharma sales.
Sector wise basic pediatrics share is declining as most of the vaccines in this sector are either off patent or newer and more effective vaccines have replaced them. Proprietary pediatrics and cancer pediatrics will define the future growth going forward. Vaccines like Prevnar (Pneumococcal vaccines), Gardasil (Cervical cancer vaccines) have crossed the sales of US$ 1 Billion by 2007. In fact Prevnar became the first vaccine to cross the US$ 2 Billion annual sales in 2007.
With the growth in internati onal travel vaccine market of adult/travel sector is also going to grow further. Malaria vaccines, Typhoid Vaccines and Japanese Encephalitis Vaccines are expected to grow further in the market. Malaria vaccine which is expected to launch in 2010 or 2011, is forecasted to be worth US$ 419 Million market by 2025. Typhoid vaccine market for travelers is expected to grow with a CAGR of 4 percent from 2003 to 2014.
Ongoing spate of mergers and accquisition in pharma sector its effect and causes on the overall industry. Such as Pfizer taking over Wyeth would cement Pfizer's position as the world's leading drugmaker. Geographic segment wise China and India vaccine market will grow considerably in future and Japanese vaccine market has also started to open up further from regulatory and political barriers. Overall the worldwide vaccine market has registered revenue of US$ 21 Billion in 2008.
Table of Contents
1. Executive Summary
2. Vaccines Market - Why is it so Attractive
2.1 Big Pharma Upping Their Commitment to Vaccines
2.2 Vaccine 'Outsiders' Jumping Onto Bandwagon (Acquisitions by Big Pharma Players)
2.3 Several New Vaccines, Many with Blockbuster Potential
3. Worldwide Vaccine Market
3.1 By Sector - Vaccine Market
3.1.1 Influenza
3.1.2 Adult/Travel
3.1.3 Proprietary Pediatrics/Adolescent
3.1.4 Enhanced Pediatrics
3.1.5 Basic Pediatrics
4. Major Vaccine Cases, Market Sizes & Future Forecast
4.1 Pneumococcal Vaccines
4.1.1 Market Size of Pneumococcal Vaccines & Future Forecast
4.2 Polio Vaccines
4.2.1 Number of Polio Cases (in 42 Countries)
4.2.2 Market Size of Polio Vaccines & Future Forecast
4.3 Meningitis Vaccines
4.3.1 Number of Meningitis Cases
4.3.2 Market Size of Meningitis Vaccines & Future Forecast
4.4 Rotavirus Vaccines
4.4.1 Number of Rotavirus Cases (in 27 Countries)
4.4.2 Market Size of Rotavirus Vaccines & Future Forecast
4.5 Tuberculosis (TB) Vaccines
4.5.1 Number of Tuberc ulosis Cases
4.5.2 Market Size of Tuberculosis Vaccines & Future Forecast
4.6 Measles, Mumps & Rubella (MMR) Vaccines
4.6.1 Number of Measles, Mumps & Rubella Cases
4.7 DTP Vaccines
4.7.1 Number of Diphtheria, Pertussis and Tetanus Cases
4.7.2 Market Size of DTP Vaccines
4.8 Hepatitis B Vaccines
4.8.1 Percent of Hepatitis B Vaccine Immunization
4.8.2 Market Size of Hepatitis B Vaccines & Future Forecast
4.9 Malaria Vaccines
4.9.1 Number of Malaria Cases
4.9.2 Market Size of Malaria Vaccines Market Future Forecast
4.10 Japanese Encephalitis Vaccines
4.10.1 Number of Japanese Encephalitis Cases
4.10.2 Market Size of Japanese Encephalitis Vaccines & Future Forecast
4.11 West Nile Vaccines
4.11.1 Number of West Nile Cases
4.11.2 Market Size of West Nile Vaccines & Future Forecast
4.12 Ebola Vaccines
4.12.1 Number of Ebola Cases
4.12.2 Market Size of Ebola Vaccines & Future Forecast
4.13 Cervical Cancer Vaccines
4.13.1 Number of Cancer & Cervical Cancer Cases
4.13.2 Market Size of Cervical Cancer Vaccines & Future Forecast
4.14 Typhoid Vaccines
4.14.1 Number of Typhoid Cases
4.14.2 Market Size of Typhoid Vaccines & Future Forecast
5. Major Geographic Markets
5.1 India Vaccine Market
5.2 China Vaccine Market
5.3 Japan Vaccine Market
5.4 US Vaccine Market
6. Competitive Landscape
6.1 Worldwide - 5 Major Companies Forecast of Vaccine Sales as Percentage of Overall Pharma Sales
6.2 Worldwide - Sales Forecast for Key Vaccine Brands
6.3 Global Economic Crisis - Increase in Vaccine Sales
For more information and latest data with graphs and tables on global vaccine market read the report published by Renub Research "World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments". We also provide sample copy of report on demand contact c.prasad@renub.com.
Published at Investorideas.com Financial Article Feed : http://www.investorideas.com/RSS/feeds/II-Art.xml
About InvestorIdeas.com: One of the first online investor resources providing in-depth information on renewable energy, greentech and water sectors.
Become an Investorideas.com Member
Gain Exclusive Insight on Leading Sectors, Global Trends, and Insider Trading Ideas, News, Articles, renewable energy and water stocks directory.
Learn more: http://www.investorideas.com/membership
Sign up for free newsletter, stock and sector news alerts at Investorideas.com
click here: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The views and opinions expressed in the research published are those of the individual companies and writers and not necessarily those of Investorideas.comŽ, or any of the industry sector portals . At the time of publication, writers may hold positions in the stocks or companies mentioned.
Investorideas.comŽ or any of the industry sector portals cannot assure accuracy of the research presented. Investors are encouraged to research and verify facts and under no circumstances is Investorideas.comŽ endorsing the content as a recommendation to buy or sell stock.
|
